Tempest Therapeutics's top three insider shareholders as of September 29, 2026 are Matthew Angel (Ceo And President, 231.48K shares), Thomas Woiwode (Director, 724 shares), Venture Capital Vi, L.P. Versant (TenPercentOwner, 72 shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Matthew Angel | Ceo And President | 0 | 231,482 | 231,482 | 99.6% | 25 Mar, 2026 |
| 2 | Thomas Woiwode | Director, TenPercentOwner | 0 | 724 | 724 | 0.3% | 03 May, 2022 |
| 3 | Venture Capital Vi, L.P. Versant | TenPercentOwner | 72 | 0 | 72 | 0.0% | 12 Aug, 2024 |
| 4 | Thomas W. Dubensky | President | 39 | 0 | 39 | 0.0% | 11 Jan, 2022 |
| 5 | Stephen R Brady | President And Ceo | 16 | 0 | 16 | 0.0% | 08 Jul, 2024 |
| 6 | Justin Trojanowski | Corporate Controller | 8 | 0 | 8 | 0.0% | 02 Jul, 2024 |
| 7 | Samuel Whiting | Chief Medical Officer | 3 | 0 | 3 | 0.0% | 03 Jul, 2024 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 04 Jun, 2026 | John D. Yee | Director | Acquired A | 25,000 | $0.00 | $0 | 25,000 | Direct |
| 04 Jun, 2026 | William Drake Richey | Director | Acquired A | 25,000 | $0.00 | $0 | 25,000 | Direct |
| 31 Mar, 2026 | Nicholas Maestas | Chief Financial Officer | Acquired A | 140,000 | $0.00 | $0 | 140,000 | Direct |
| 31 Mar, 2026 | Justin Trojanowski | Corporate Controller | Acquired A | 22,000 | $0.00 | $0 | 22,000 | Direct |
| 24 Mar, 2026 | Matthew Angel | Ceo And President | Acquired P | 231,482 | $2.16 | $500.00K | 231,482 | Indirect |
| 04 Feb, 2026 | Matthew Angel | Ceo And President | Acquired A | 269,621 | $0.00 | $0 | 269,621 | Direct |
| 27 Jan, 2026 | Geoffrey Nichol | Director | Acquired A | 1,230 | $0.00 | $0 | 1,230 | Direct |
| 27 Jan, 2026 | Christine A Pellizzari | Director | Acquired A | 1,230 | $0.00 | $0 | 1,230 | Direct |
| 27 Jan, 2026 | Michael Raab | Director | Acquired A | 1,230 | $0.00 | $0 | 1,230 | Direct |
| 27 Jan, 2026 | Ronit Simantov | Director | Acquired A | 1,230 | $0.00 | $0 | 1,230 | Direct |
| 02 Jan, 2025 | Justin Trojanowski | Corporate Controller | Acquired A | 30,000 | $0.00 | $0 | 10 | Direct |
| 02 Jan, 2025 | Stephen R Brady | President And Ceo | Acquired A | 550,000 | $0.00 | $0 | 188 | Direct |
| 02 Jan, 2025 | Samuel Whiting | Chief Medical Officer | Acquired A | 270,000 | $0.00 | $0 | 92 | Direct |
| 02 Jan, 2025 | Nicholas Maestas | Chief Financial Officer | Acquired A | 200,000 | $0.00 | $0 | 68 | Direct |
| 08 Aug, 2024 | Venture Capital Vi, L.P. Versant | TenPercentOwner | Disposed S | 400,000 | $3,948.81 | $1.58Bn | 204 | Direct |
| 12 Aug, 2024 | Venture Capital Vi, L.P. Versant | TenPercentOwner | Disposed S | 387,999 | $3,218.77 | $1.25Bn | 72 | Direct |
| 03 Jul, 2024 | Stephen R Brady | President And Ceo | Acquired P | 35,000 | $6,171.38 | $216.00Mn | 16 | Direct |
| 02 Jul, 2024 | Samuel Whiting | Chief Medical Officer | Acquired P | 4,672 | $6,229.88 | $29.11Mn | 3 | Direct |
| 28 Jun, 2024 | Justin Trojanowski | Corporate Controller | Acquired P | 7,500 | $6,317.62 | $47.38Mn | 8 | Direct |
| 13 Jun, 2024 | Christine A Pellizzari | Director | Acquired A | 16,000 | $0.00 | $0 | 5 | Direct |